New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
08:26 EDTICPT, GEVALeerink reiterates caution on Intercept ahead of FLINT data
Leerink says the physicians it spoke to at its Healthcare Insights Conference who treat liver diseases were cautious on Intercept's (ICPT) obeticholic acid's clinical potential in non-alcoholic steatohepatitis due to its effect on LDL-C. Leerink remains cautious on the stock ahead of full FLINT data in the second half of 2014, as it believes there is as much if not more downside than upside due to safety concerns. The firm adds the specialists noted that they have screened and not found any patients that warrant treatment with an expensive enzyme replacement therapy, such as Synageva's (GEVA) sebelipase alfa.
News For ICPT;GEVA From The Last 14 Days
Check below for free stories on ICPT;GEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 14, 2014
11:46 EDTICPTOptions with decreasing implied volatility
Subscribe for More Information
August 13, 2014
10:33 EDTICPTOptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR ZU ICPT MNKD UBNT OLED RAX UVXY VNDA
August 12, 2014
16:32 EDTICPTOn The Fly: Closing Wrap
Subscribe for More Information
12:37 EDTICPTOn The Fly: Midday Wrap
Subscribe for More Information
11:10 EDTICPTHigh option volume stocks
10:18 EDTICPTIntercept rallies sharply, retraces, levels to watch
The shares gapped open to $345.62 this morning, rallied to a high of $349.08, and have since been moving lower in price. With last price at $307.03 the stock is not far from the top of the prior trading range which was near the $300 area. Holding above that $300 level is important if the stock is going to regain a bullish footing. A break back down into the prior range of $210 at the low and $300 at the high would leave the stock in neutral mode technically. Resistance is at $313.14, based on current price.
10:15 EDTICPTIntercept surges after reporting data for liver disease drug OCA
Subscribe for More Information
10:00 EDTICPTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
08:32 EDTICPTIntercept Pharmaceuticals volatility expected to move on trial data
Subscribe for More Information
07:53 EDTICPTIntercept price target raised to $500 from $395 at Deutsche Bank
Subscribe for More Information
06:30 EDTICPTIntercept upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Intercept to Outperform citing an increased probability of success in NASH following last night's data. The firm raised its price target for shares to $445 from $270 saying it was encouraged by the removal of the prior imbalance in serious adverse events.
06:20 EDTICPTIntercept upgraded to Outperform from Market Perform at Leerink
06:19 EDTICPTIntercept data for liver disease drug 'highly positive, says Citigroup
Subscribe for More Information
August 11, 2014
18:29 EDTICPTOn The Fly: After Hours Movers
UP AFTER EARNINGS: DealerTrack (TRAK), up 11.3%... DTS Inc. (DSTI), up 12.8%... Globalstar (GSAT), up 1.6%... Halozyme Therapeutics (HALO), up 2.4%. ALSO HIGHER: Intercept Pharmaceuticals (ICPT), up 57.7% after announcing that 46% of OCA group met FLINT endpoint as well as reporting second quarter results... Cempra (CEMP), up 5.8% following Intercept Pharmaceuticals' FLINT announcement... Scotts Miracle-Gro (SMG), up 3.6% after board approves a $500M share repurchase authorization and announces a $2.00 per share special dividend. DOWN AFTER EARNINGS: Galena Biopharma (GALE), down 13.4%... Nuance Communications (NUAN), down 9.7%... Millennial Media (MM), down 7.1%... MasTec (MTZ), down 3.6%... Turtle Beach (HEAR), down 3.5%... magicJack (CALL), down 5.8%... Geron (GERN), down 2.4%. ALSO LOWER: Sprouts Farmers Market (SFM), down 3.7% after filing to sell 15M shares of common stock for holders.
17:18 EDTICPTIntercept up 54% to $363 after OCA data, Q2 earnings
Subscribe for More Information
17:11 EDTICPTIntercept says 46% of OCA group met FLINT endpoint vs. 21% for placebo group
Subscribe for More Information
16:24 EDTICPTIntercept reports Q2 EPS $1.51, may not compare to consensus (12c)
Subscribe for More Information
15:32 EDTICPTNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Ventas (VTR), consensus $1.09; Nuance Communications (NUAN), consensus 27c; Intercept Pharmaceuticals (ICPT), consensus (12c); Rackspace Hosting (RAX), consensus 16c; Opko Health (OPK), consensus (9c); Mindray Medical (MR), consensus 54c; Chimera Investment (CIM), consensus 9c; Globalstar (GSAT), one estimate (4c); 51job (JOBS), consensus 32c; Dealertrack Technologies (TRAK), consensus 373c; Caesars Entertainment (CZR), consensus ($1.19); Towerstream (TWER), consensus (10c); Resolute Energy (REN), consensus 1c; Forest Oil (FST), consensus (2c).
August 8, 2014
06:34 EDTICPTIntercept volatility elevated into data
Intercept overall option implied volatility of 106 is above its 26-week average of 97 according to Track Data, suggesting large price movement into the expected release of Phase 2b FLINT 72 week data.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use